TMS Co., Ltd. (JP:4891)
:4891
Want to see JP:4891 full AI Analyst Report?
Top Page
TMS Co., Ltd.
(4891)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥113.00
▼(-12.40% Downside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by weak financial performance (recent multi-year losses, absent/limited revenue, and ongoing cash burn), only partly offset by the low-leverage balance sheet. Technicals add further pressure with price below all major moving averages and negative MACD. Valuation offers limited support because the negative P/E reflects unprofitable operations and no dividend yield is available.
Positive Factors
Low leverage / no debt
No reported debt meaningfully lowers fixed financing costs and reduces short‑term liquidity pressure. A conservatively financed balance sheet provides durable financial optionality to pursue R&D, partnerships or non‑dilutive funding and buys time to execute milstones without interest burden.
Negative Factors
Persistent negative cash flow
Repeated negative operating and free cash flow over multiple years indicates structural cash burn, increasing funding risk and undermining internal financing capacity. Over time this limits strategic options, pressures runway, and makes the company reliant on external capital or partnerships to continue operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
No reported debt meaningfully lowers fixed financing costs and reduces short‑term liquidity pressure. A conservatively financed balance sheet provides durable financial optionality to pursue R&D, partnerships or non‑dilutive funding and buys time to execute milstones without interest burden.
Read all positive factors
TMS Co., Ltd. (4891) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.33B
Dividend YieldN/A
Average Volume (3M)256.91K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.99
Shares Outstanding45,565,765
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
TMS Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The...
How the Company Makes Money
null...
TMS Co., Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95B |
| Gross Profit | -501.00K | -314.40K | -3.71M | -6.95M | -6.60M | 1.74B |
| EBITDA | -1.02B | -836.05M | -655.89M | -937.00M | -513.55M | 1.14B |
| Net Income | -699.20M | -859.27M | -660.55M | -960.04M | -860.92M | 1.08B |
Balance Sheet | ||||||
| Total Assets | 3.21B | 2.87B | 3.03B | 3.55B | 3.79B | 2.74B |
| Cash, Cash Equivalents and Short-Term Investments | 3.18B | 2.78B | 2.92B | 3.45B | 3.58B | 2.60B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 122.98M | 95.00M | 216.78M | 97.69M | 76.16M | 286.78M |
| Stockholders Equity | 3.09B | 2.77B | 2.82B | 3.46B | 3.71B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -782.43M | -524.60M | -826.17M | -702.14M | 1.25B |
| Operating Cash Flow | 0.00 | -779.89M | -493.76M | -822.81M | -688.42M | 1.26B |
| Investing Cash Flow | 0.00 | -2.54M | -30.84M | -3.36M | -13.72M | -16.96M |
| Financing Cash Flow | 0.00 | 640.52M | 919.00K | 688.13M | 1.69B | 246.48M |
TMS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥6.90B | 43.54 | ― | ― | 4.93% | -59.54% | |
45 Neutral | ¥17.93B | -9.59 | ― | ― | ― | 6.10% | |
43 Neutral | ¥5.33B | -7.95 | ― | ― | ― | ― | |
43 Neutral | ¥35.24B | -10.48 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥12.08B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.34B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4891
TMS Co., Ltd.
117.00
-54.00
-31.58%
JP:4593
Healios KK
261.00
-280.00
-51.76%
JP:4599
StemRIM Inc.
286.00
-69.00
-19.44%
JP:4978
ReproCELL Inc.
127.00
-65.00
-33.85%
JP:7096
StemCell Institute
673.00
-397.00
-37.10%
JP:7776
CellSeed Inc.
213.00
-302.00
-58.64%
TMS Co., Ltd. Corporate Events
TMS Posts Quarterly Loss, Maintains Strong Equity Base and Suspends Guidance
May 15, 2026
TMS Co., Ltd. reported a non-consolidated net loss of ¥204 million for the three months ended March 31, 2026, with operating and ordinary losses of ¥203 million and basic earnings per share of negative ¥4.49. Despite the loss, the c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.